Recombinant Antigens Based on Non-Glycosylated Regions from RBD SARS-CoV-2 as Potential Vaccine Candidates against COVID-19

The Receptor-Binding Domain (RBD) of the Spike (S) protein from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has glycosylation sites which can limit the production of reliable antigens expressed in prokaryotic platforms, due to glycan-mediated evasion of the host immune response. How...

Descripción completa

Detalles Bibliográficos
Autores principales: Núñez-Muñoz, Leandro, Marcelino-Pérez, Gabriel, Calderón-Pérez, Berenice, Pérez-Saldívar, Miriam, Acosta-Virgen, Karla, González-Conchillos, Hugo, Vargas-Hernández, Brenda, Olivares-Martínez, Ana, Ruiz-Medrano, Roberto, Roa-Velázquez, Daniela, Morales-Ríos, Edgar, Ramos-Flores, Jorge, Torres-Franco, Gustavo, Peláez-González, Diana, Fernández-Hernández, Jorge, Espinosa-Cantellano, Martha, Tapia-Sidas, Diana, Ramírez-Pool, José Abrahan, Padilla-Viveros, América, Xoconostle-Cázares, Beatriz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402574/
https://www.ncbi.nlm.nih.gov/pubmed/34452053
http://dx.doi.org/10.3390/vaccines9080928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402574/
https://www.ncbi.nlm.nih.gov/pubmed/34452053
http://dx.doi.org/10.3390/vaccines9080928

Ejemplares similares